GlassScriptPhysician profile
Kaylynn Young
NPI 1750374203
$4,841.73
in general payments reported to CMS, 2019-2025
41 companies · $569 in 2025
The $569 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,158 · 2022: $736 · 2023: $1,050 · 2024: $1,328 · 2025: $569.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,947.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,947.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $989.55 | 2021-2025 | |
| Glaxosmithkline, LLC. | $486.86 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $428.50 | 2021-2024 | Jardiance |
| Lilly USA, LLC | $383.20 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $340.54 | 2021-2024 | Freestyle Libre 3 |
| Novo Nordisk INC | $267.57 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $207.70 | 2021-2025 | Repatha, Otezla, Repatha |
| Corium, LLC | $154.98 | 2023-2024 | Azstarys, Azstarys |
| Astrazeneca Pharmaceuticals LP | $151.11 | 2021-2025 | Breztri |
| Pfizer INC. | $130.06 | 2021-2025 | |
| Antares Pharma, INC. | $112.14 | 2021-2024 | Xyosted, Tlando, Nocdurna |
| Dexcom, INC. | $104.34 | 2022-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Exact Sciences Corporation | $102.44 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Astellas Pharma US INC | $90.79 | 2021-2024 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $70.88 | 2021-2023 | Xarelto |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaylynn Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.